Jm Arizon

Jm Arizon

Auto-generated profile, based on publicly available information

Jm Arizon

Hospital Reina Sofia, Córdoba, Spain

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2008 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MCM. G. Crespo-Leiro
M. G. Crespo-Leiro
LAL. Alonso-Pulpón
L. Alonso-Pulpón
JPJ. A. Vázquez de Prada
J. A. Vázquez de Prada
LAL. Almenar
L. Almenar
JAJ. M. Arizón
J. M. Arizón
JMJavier Muñiz
Javier Muñiz
The Spanish Post-Heart-Transplant Tumour Registry comprises data on neoplasia following heart transplantation (HT) for all Spanish HT patients (1984–2003). This retrospective analysis of 3393 patients investigated the incidence and prognosis of neoplasia, and the influence of antiviral prophylaxis. About 50% of post-HT neoplasias were cutaneous, and 10% lymphomas. The cumulative incidence of skin cancers and other nonlymphoma cancers increased with age at HT and with time post-HT (from respectively 5.2 and 8.9 per 1000 person-years in the first year to 14.8 and 12.6 after 10 years), and was greater among men than women. None of these trends held for lymphomas. Induction therapy other than with IL2R-blockers generally increased the risk of neoplasia except when acyclovir was administered prophylactically during the first 3 months post-HT; prophylactic acyclovir halved the risk of lymphoma, regardless of other therapies. Institution of MMF during the first 3 months post-HT reduced the incidence of skin cancer independently of the effects of sex, age group, pre-HT smoking, use of tacrolimus in the first 3 months, induction treatment and antiviral treatment. Five-year survival rates after first tumor diagnosis were 74% for skin cancer, 20% for lymphoma and 32% for other tumors.

1 October 2010 in Transplantation Proceedings
Verified
Journal Article
Open access
BMBeatriz Diaz Molina
Beatriz Diaz Molina
MLM.G.C. Leiro
M.G.C. Leiro
LPL.A. Pulpón
L.A. Pulpón
SMS. Mirabet
S. Mirabet
JYJ.F. Yañez
J.F. Yañez
JMJavier Muñiz
Javier Muñiz
The incidence of skin cancer in heart transplant (HT) patients is higher than in the general population, reversing the proportion of cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) with a predominance of the former. The etiologic role of new immunosuppressants is not well known. We sought to ascertain the incidence of SCC and BCC in HT patients and the risk factors for its occurrence. We report the incidence of all types of post-HT skin cancer, SCC, and BCC among adult HT patients in Spain (4089 subjects) as well as the influence of gender, age at heart transplant, immunosuppression, and sunlight exposure. The incidence rates of SCC and BCC, per 1000 persons/year, were 8.5 and 5.2, respectively. Males had a higher risk of SCC but not BCC. Induction therapy increased the risk of SCC and BCC. The relative risk of mycophenolate mofetil (MMF) was 0.3 (0.2-0.6; P<.0005) and azathioprine (AZA) 1.8 (1.2-2.7; P<.0032) for SCC, whereas tacrolimus and cyclosporine showed no difference. The relative risk of BCC was not affected by any immunosuppressant. Age at transplantation>45 years, induction therapy use, and high sunshine zone were risk factors for both SCC and BCC. Different immunosuppressive agents have different risks of nonmelanoma skin cancer, as AZA increases the risk of SCC and MMF is a protective factor. The relative risk of BCC was not affected by any immunosuppressor.

1 April 2006 in Human Immunology
Verified
Journal Article
Closed access
JLJ. Luque
J. Luque
MLM Isabel Torres López
M Isabel Torres López
MAM D Aumente
M D Aumente
JMJ. Marı́n
J. Marı́n
GGG. Garcı́a-Jurado
G. Garcı́a-Jurado
JPJ. Peña
J. Peña

28 May 2009 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ERE. Roig
E. Roig
LAL. Almenar
L. Almenar
FGF. González-Vílchez
F. González-Vílchez
GRG. Rábago
G. Rábago
Juan F. Delgado JiménezJuan F. Delgado Jiménez
Juan F. Delgado Jiménez
OTOn Behalf Of The Spanish Register For Heart Trasplantation
On Behalf Of The Spanish Register For Heart Trasplantation
Amyloidosis (Am), a systemic disease, has poor prognosis because of organ damage produced by protein deposition in the extracellular space. Although heart transplantation (HTx) is possible, donor availability concerns and high mortality make this approach controversial. The Spanish Registry for Heart Transplantation includes 25 Am patients (54 ± 9 years): 13 with AL type, 2 with AA and 10 with TTR mutation. Fifteen patients (60%) died during follow-up (4.9 ± 1.3 years): 9 AL-Am patients, both AA-Am patients and 4 with TTR-Am. HTx survival for Am patients was similar to patients without Am at 1 month but significantly worse at 5 years: 46% versus 78% (p < 0.02). Of 10 AL-Am patients undergoing successful HTx, 4 died of systemic Am. Stem cell transplantation was performed in 3 (1 died of acute rejection). Five of 10 patients with TTR-Am underwent liver transplant; 4 remained alive at the last follow-up. Findings include poor outcome for AL-Am patients despite HTx and better survival for TTR-Am patients if HTx is associated with liver transplantation. Given the shortage of donors and poor outcome for Am patients, we would recommend that HTx be reserved for patients without or with mild systemic Am and be supplemented by additional therapies as indicated.

1 January 2014 in International Journal of Cardiology
Verified
Journal Article
Closed access
FGFrancisco Gonzalez-Vilchez
Francisco Gonzalez-Vilchez
JPJ.A. Vazquez de Prada
J.A. Vazquez de Prada
MPM.J. Paniagua
M.J. Paniagua
MGM. Gomez-Bueno
M. Gomez-Bueno
JAJ.M. Arizon
J.M. Arizon
TBT. Blasco
T. Blasco

31 July 2010 in Transplantation Reviews
Verified
Journal Article
Closed access
NMNicolás Manito
Nicolás Manito
Juan F. Delgado JiménezJuan F. Delgado Jiménez
Juan F. Delgado Jiménez
MCMaria G. Crespo-Leiro
Maria G. Crespo-Leiro
FGFrancisco Gonzalez-Vilchez
Francisco Gonzalez-Vilchez
LALuis Almenar
Luis Almenar
JSJavier Segovia
Javier Segovia